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Abstract
Multivariate linear growth curves were used to model high-density lipoprotein (HDL), low-density
lipoprotein (LDL), triglycerides (TG), and systolic blood pressure (SBP) measured during four
exams from 1659 independent individuals from the Framingham Heart Study. The slopes and
intercepts from each of two phenotype models were tested for association with 348,053 autosomal
single-nucleotide polymorphisms from the Affymetrix Gene Chip 500 k set. Three regions were
associated with LDL intercept, TG slope, and SBP intercept (p <1 . 4 4×1 0
-7). We observed results
consistent with previously reported associations between rs599839, on chromosome 1p13, and
LDL. We note that the association is significant with LDL intercept but not slope. Markers on
chromosome 17q25 were associated with TG slope, and a single-nucleotide polymorphism on
chromosome 7p11 was associated with SBP intercept. Growth curve models can be used to gain
more insight on the relationships between SNPs and traits than traditional association analysis
when longitudinal data has been collected. The power to detect association with changes over time
may be limited if the subjects are not followed over a long enough time period.
Background
Cardiovascular disease (CVD) is the leading cause of
death in the United States and is a significant cause of
disability. Worldwide, heart disease is on the rise, and is
predicted to become the leading cause of death and
disability by 2020 [1].
In order to identify common risk factors leading to CVD,
several large-scale epidemiological studies have been
undertaken. Most notable is the Framingham Heart
Study (FHS), a prospective study which was started over
50 years ago and is still ongoing. It was designed to
follow the development of CVD over time in a large
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symptoms of CVD. The original participants underwent
extensive medical testing approximately every 2 years,
and more recently recruited individuals have also been
followed regularly. Through the data arising from the
FHS, several major risk factors for CVD have been
identified, including hypertension, high blood choles-
terol, smoking, obesity, and diabetes. In addition, results
from the study have demonstrated significant effects of
demographic factors such as age and sex.
The longitudinal design of the FHS allows for the study
of how certain traits change over time. The analysis of
time-dependent data can range from simple plots to
complex survival or multilevel modelling. In this paper,
we use a latent growth curve (LGC) model to examine
t h ec h a n g eo v e rt i m ei nl e v e l so fs y s t o l i cb l o o dp r e s s u r e
(SBP), high-density lipoprotein (HDL), low-density
lipoprotein (LDL), and triglycerides (TG), as well as to
explore the relationship between these four traits, which
are known to affect the risk of developing CVD.
Association analysis was performed to identify genetic
factors that are associated with mean baseline values of
each trait, as well as the changes over time, using subjects
from the FHS.
Methods
D e t a i l sa b o u ts a m p l er e c r u i t m e n tc a nb ef o u n di n
Cupples et al. [2] and Splansky et al. [3]. Briefly, 5209
subjects aged 29 to 62 were recruited between 1948 and
1953 from the town of Framingham, Massachusetts
(Original Cohort). Between 1971 and 1975, an addi-
tional 5124 individuals were recruited, who were the
offspring of the Original Cohort and the offspring’s
spouses (Offspring Cohort). Finally, between 2002 and
2005, 4095 third generation individuals (children of the
Offspring Cohort) were recruited (Generation 3). Data
from four examinations are available for each of the
Original and Offspring Cohort, while data from a single
examination are available for Generation 3.
Samples used for analysis
Because individuals from the Original Cohort fasted
before only one of the four exams, the lipid profiles
obtained from these individuals were not ideal for
longitudinal analyses. We therefore restricted our analy-
sis to members of the Offspring Cohort, who fasted
before all four exams. We selected independent members
of the Offspring Cohort as follows. Starting with the
original 1538 families, the Generation 3 cohort was
removed, which split the pedigrees into 3379 indepen-
dent sub-pedigrees. Individuals belonging to the Off-
spring Cohort who had phenotype and genotype data
were considered for inclusion in the analysis. We selected
independent individuals from this set. In sub-pedigrees
in which multiple sets of individuals could be chosen,
we randomly selected a set that gave the largest number
of independent individuals (as determined by the
kinship coefficient). This resulted in 1488 individuals.
An additional 171 samples without family data were
added, for a total of 1659 independent individuals.
Phenotypic modeling
A linear LGC model was fit to longitudinal measure-
ments of SBP, HDL, LDL, and TG. One of the strengths of
LGC modeling is that it allows the study of multiple
outcomes over time in a multivariate framework, which
is particularly useful in investigating the change in
phenotype values and assessing cross-phenotype rela-
tionships [4]. Two models were analyzed, corresponding
to two sets of covariates. In the first set, sex, baseline age,
and body mass index (BMI), and a variable to indicate a
diagnosis of diabetes at any time during the study were
included as time-invariant covariates, and the number of
cigarettes smoked per day was considered to be a time-
varying covariate. The second covariate set was identical,
except that BMI was allowed to vary over time. In both
models, individuals who reported taking medication at
the time of examination had their relevant trait values
adjusted by the addition of a constant. This procedure
has been shown to provide good power to detect a
genetic effect and to have little bias in effect size
estimation, while being relatively robust to the exact
value of the constant [5]. For individuals taking
medication for hypertension, SBP was increased by 10
mm Hg [6]. For individuals taking lipid-lowering
medication, the reported HDL values were adjusted by
-2.15 mg/dL, LDL by +43.23 mg/dL, and TG by +24.92
mg/dL, based on previously reported average effects of
statins and fibric acid derivatives in primarily White
subjects [7]. Because information on the type of
medication was not provided for our sample, the effects
of the two types of drugs were combined using a
weighted average. Missing values were imputed using the
missing-at-random assumption. The models were fit
using the software Mplus version 5 [8]. Because the
distribution of TG was skewed, the robust maximum-
likelihood method was used. LDL was calculated for
each observation using the Friedewald equation [9], or
was considered to be missing if TG>400 mg/dL.
Genotypes
Genotyping was conducted using the Affymetrix Gene-
Chip Human Mapping 500 k Array Set, using the 250 k
Sty and 250 k Nsp platforms. Only autosomal markers
were considered for analysis. The original set of markers
consisted of 487,014 autosomal markers with known
chromosomal assignments and physical positions. We
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<95%, based on all 6848 genotyped individuals. Markers
were also removed if the minor allele frequency was <5%
(101,422 markers) or the p-value from an exact test for
Hardy-Weinberg equilibrium [10] was <10
-6 (4945
markers). Thus, the final marker set consisted of
348,053 single-nucleotide polymorphisms (SNPs).
Association analysis
Individual-specific intercepts and slopes were obtained
from the growth curve models, for each of the
phenotypes SBP, HDL, LDL, and TG. These phenotypic
summaries were examined for association with each
marker separately using linear regression, as implemen-
ted in the program PLINK v1.04 [11], assuming an
additive genetic model. Markers associated with slope
traits affect the change over time of a particular
phenotype, while markers associated with intercept traits
affect the initial value.
Results and discussion
Description of phenotypes and covariates
The sample was composed of 1659 independent subjects
who were examined at four different time points. Details
about the raw variables and covariates are described in
Table 1, before and after adjustment for medication use.
The amount of missing phenotypic data varied between
exams. Exam 1 was the most complete, with a missing
rate of 0.7% for the variables used in this study. Exam 3
was the least complete, with a missing rate of 13.9%,
mostly due to 208 individuals who did not attend this
examination. Exams 5 and 7 had missing rates of 6.3%
and 5.0%, respectively. Summaries of the slopes and
intercepts obtained after fitting the growth curve models
to HDL, LDL, TG, and SBP are shown in Table 2. With
the exception of TG, the trait values did not change much
over the four time points, as indicated by the small
slopes. The time-invariant covariates age, sex and
diabetes were significant at the 5% level for the intercept
of all traits, but not necessarily the slopes (data not
shown). Comparing the model in which BMI was treated
as a time-invariant covariate with the model in which
BMI was allowed to vary over time, the distributions of
the estimates were shifted in location for all traits, but
the variances were largely unchanged.
Association analysis
We tested 348,053 markers for association with the
intercepts and slopes of HDL, LDL, TG, and SBP. A total
of six markers in three regions were associated in at least
one of the two models, using a Bonferroni cutoff of
p <1 . 4 4×1 0
-7 (Table 3). The most significant
association was between LDL intercept and rs599839
on chromosome 1p13 (p =3 . 0 4×1 0
-10 in the model
where BMI was time-varying). The minor G allele was
associated with a reduction in LDL intercept values. This
marker is approximately 250 kb upstream of PSRC1,
which encodes a proline-rich protein. This marker was
recently shown to be associated with LDL measured at a
single examination in a meta-analysis [12], and was also
associated with coronary artery disease [13]. In these two
studies, the major A allele was associated with an
increase in LDL levels, or risk of coronary artery disease,
consistent with the direction we report here. Although
Table 1: Sample characteristics
a
Variable Exam 1 Exam 3 Exam 5 Exam 7
Examined
b 1659 (100)
a 1451 (87.5) 1563 (94.2) 1597 (96.3)
Exam dates 1971 to 1975 1983 to 1987 1991 to 1995 1998 to 2001
Males 754 (45.4) 667 (46.0) 711 (45.5) 724 (45.3)
Age, years 34.8 ± 9.0 47.3 ± 9.0 54.3 ± 8.9 61.0 ± 8.9
BMI, kg/m
2 25.0 ± 4.1 25.9 ± 4.6 27.2 ± 4.7 27.9 ± 5.2
SBP, mm Hg 118.9 ± 14.0
119.1 ± 14.2
d
122.3 ± 16.0
123.6 ± 17.3
124.7 ± 18.7
126.3 ± 20.0
126.3 ± 18.8
129.4 ± 20.5
Hypertension medication 30 (1.8) 189 (13.0) 251 (16.1) 502 (31.4)
HDL, mg/dL 51.5 ± 14.4
51.5 ± 14.4
52.0 ± 14.8
52.0 ± 14.8
50.5 ± 15.0
50.4 ± 15.1
54.5 ± 17.0
54.1 ± 17.2
LDL, mg/dL 123.2 ± 34.3
123.4 ± 34.7
136.7 ± 36.3
137.1 ± 36.9
126.3 ± 32.4
129.4 ± 35.3
119.8 ± 31.6
128.5 ± 32.8
TG, mg/dL 83.6 ± 62.7
83.7 ± 62.2
114.4 ± 128.4
114.6 ± 128.6
145.4 ± 119.3
147.3 ± 120.3
135.8 ± 86.8
140.8 ± 88.8
Cholesterol medication 7 (0.4) 14 (1.0) 117 (7.5) 321 (20.1)
Smokers 654 (39.6) 380 (26.2) 269 (17.2) 206 (12.9)
Diabetes
c 175 (10.5)
aValues are mean ± standard deviation for quantitative variables, and count (%) for qualitative variables.
bIndividuals with a recorded age at exam.
cIndividuals who developed diabetes at any point during the study.
dValues in italics are means and standard deviations after adjustment for medication use.
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associated with LDL slope (p = 0.14), indicating that it
may not play a role in the change of LDL levels over
t i m e ,a tl e a s ti nt h ea g er a n g eo fi n d i v i d u a l ss t u d i e dh e r e .
T h i sS N Pa l s os h o w e dt h em o s ts i g n i f i c a n ta s s o c i a t i o n
with LDL intercept in the model in which BMI was time-
invariant (p =2 . 6 2×1 0
-9).
SNP rs6501683 on 17q25 was associated with TG slope
(p =3 . 8 9×1 0
-8 a n d2 . 9 8×1 0
-9 for BMI time-invariant
and BMI time-varying models, respectively). Three other
markers in the same region also show association,
although at lower levels of significance. All four markers
are in nearly complete linkage disequilibrium (r
2 =0 . 9 9
or 1 for all pairs of markers) in this data. TG intercept
was not associated with these markers (p =0 . 1 9a n d0 . 2 0
for BMI time-invariant and BMI time-varying models,
respectively, for rs6501683).
On chromosome 7p11, rs11976165 was associated with
SBP intercept (p =6 . 8 8×1 0
-8)i nt h em o d e li nw h i c h
BMI was treated as a time-invariant covariate. In the
model in which BMI was treated as a time-varying
covariate, the p-value for this SNP falls just above the
significance cutoff used here (p =1 . 4 5×1 0
-7). This
region is peri-centromeric, and is not near any known
genes. The observed association was only with the
intercept (p = 0.20 for SBP slope, BMI time-invariant
model).
Because there may be genes in common to the change in
BMI, lipid levels, and SBP, two models were fit differing
only in the treatment of the covariate BMI. One model
was fit using baseline BMI as a covariate, and another in
which BMI was included as a time-varying covariate. The
model in which BMI was time-invariant may be better
able to detect association with regions affecting both
BMI and the traits of interest. However, in the dataset
used here, the association results for the two models
were very similar.
In order to account for the effect of trait-altering
medications, we adjusted medicated values by adding a
constant to the relevant observations. Adjusting for
medication use by including it as a time-varying
covariate in the model did not change the association
patterns between the traits and markers, although a
slight shrinkage bias was observed in the effect size
estimates (data not shown). Because only a small
proportion of individuals reported taking trait-altering
Table 2: Characteristics of the intercepts and slopes from the growth curve models
a
BMI time-invariant
b BMI time-varying
c
Trait Intercept Slope Slope/intercept ratio (%) Intercept Slope Slope/intercept ratio (%)
HDL 51.6 ± 10.9 0.37 ± 2.20 0.72 74.9 ± 9.9 1.75 ± 2.24 2.33
LDL 126.4 ± 29.0 1.36 ± 5.66 1.07 85.6 ± 28.2 7.85 ± 5.18 9.17
TG 83.2 ± 50.7 20.86 ± 20.41 25.03 -16.4 ± 48.8 12.31 ± 20.97 74.92
SBP 120.3 ± 10.8 3.08 ± 3.31 2.56 93.5 ± 9.2 0.09 ± 3.25 0.10
aValues are mean ± standard deviation. Units are mg/dL for HDL, LDL, and TG intercept; mm Hg for SBP intercept; mg/dL per visit for HDL, LDL, and
TG slope; mm Hg per visit for SBP intercept.
bModel included sex, baseline age, diabetes status, and baseline BMI as time-invariant covariates, and number of cigarettes smoked per day as a time-
varying covariate.
cModel identical to BMI time-invariant model, except BMI was treated as a time-varying covariate.
Table 3: Association results for markers with p < 1.44 × 10
-7
BMI time-invariant
a BMI time-varying
b
Trait Locus Marker Minor allele (frequency) ˆ β (SE)
c p-Value ˆ β (SE)
c p-Value
LDL intercept 1p13 rs599839 G (0.23) -7.14 (1.19) 2.62 × 10
-9 -7.33 (1.16) 3.04 × 10
-10
TG slope 17q25 rs6501683 T (0.23) 4.73 (0.86) 3.89 × 10
-8 5.25 (0.88) 2.98 × 10
-9
17q25 rs7213663 C (0.24) 4.26 (0.84) 4.98 × 10
-7 4.68 (0.87) 7.47 × 10
-8
17q25 rs8074960 C (0.24) 4.31 (0.84) 3.27 × 10
-7 4.71 (0.86) 5.51 × 10
-8
17q25 rs8075297 C (0.24) 4.17 (0.83) 5.30 × 10
-7 4.57 (0.85) 8.99 × 10
-8
SBP intercept 7p11 rs11976165 T (0.20) 2.53 (0.47) 6.88 × 10
-8 2.11 (0.40) 1.45 × 10
-7
aPhenotypic model included sex, baseline age, diabetes status and baseline BMI as time-invariant covariates, and number of cigarettes smoked per day
as a time-varying covariate.
bPhenotypic model identical to BMI time-invariant model, except BMI was treated as a time-varying covariate.
c ˆ β represents the regression coefficient from the association analysis, and estimates the effect on the trait value by adding one copy of the minor
allele; SE, standard error.
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expect the choice of medication adjustment method to
have a strong effect on the overall results.
Because the distribution of TG was non-normal, we used
robust maximum-likelihood estimation [14], as imple-
mented in the Mplus statistical software [8]. The
distributions of the resulting intercepts and slopes were
less skewed, but still showed a long upper tail, which
could affect inference of the association tests. Addition-
ally, the distribution of the TG intercepts from the model
in which BMI was time-varying tended to be negative.
This may indicate that the departure from normality was
too extreme to be modeled well by robust techniques, or
that a linear trajectory was not an appropriate assump-
tion. A log transformation could normalize the distribu-
tion, at the cost of decreased interpretability of the
estimates.
We did not explicitly model time, as measured by age at
exam, in the growth model. This implicitly assumes that
the exams were evenly spaced, an assumption which
seems reasonable, on average, between Exams 3, 5, and
7, but not between Exams 1 and 3. The model could be
improved by including a more appropriate measure of
time.
The estimates of the slopes tended to be small for all
traits, with the exception of TG. Thus, in this sample, the
trait values tended to remain stable over time, and
perhaps it is not surprising that significant association
with a slope trait was only observed with TG. The
heritability of the intercepts and slopes from this study
cannot be calculated because independent samples were
used. However, other analyses of the FHS data showed
that the heritability of lipid levels taken at a single exam
is moderate (h
2 = 0.52, 0.59, and 0.48 for HDL, LDL, and
TG, respectively) [15], while the heritability of SBP at a
single exam is lower (h
2 = 0.28) [16]. Studies investigat-
ing the heritability of the change in phenotypes over
time are less common, although the heritability of the
SBP slope was estimated to be similar to that of a single
exam (h
2 = 0.23) in the FHS data [17].
Conclusion
The longitudinal nature of the FHS data was exploited
using LGC models, which allowed the study of multiple
phenotypes simultaneously. Consequently, the effect of
each phenotype on each other was accounted for,
through pairwise correlations, in the model. An associa-
tion between a marker and a particular trait, therefore,
can be interpreted as an association with the trait, after
the effects of the covariates and the remaining three traits
have been accounted for. We used phenotypic
summaries from these models to search for SNPs
associated with the mean value or change over time of
lipid and blood pressure phenotypes across the genome.
Because long-term averages of lipid phenotypes have
been shown to be heritable [16], this strategy may allow
us to distinguish genes contributing to overall levels of
traits from those contributing to changes over time.
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